MAP2K7 and neoplasm: Ulixertinib demonstrates potent anti-tumor activity in preclinical studies using cell lines and xenograft models with mutations in BRAF, RAS, and MEK genes, as well as in cases of acquired resistance to BRAF and MEK inhibitors [40,53].